BiotechTube
Tolremo Therapeutics

Tolremo Therapeutics

Basel, Switzerland· Est.
tolremo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $33.5M

Overview

Tolremo Therapeutics is a private, clinical-stage biotech tackling a fundamental challenge in oncology: non-genetic, adaptive resistance to targeted cancer therapies. The company's core discovery is the role of CBP/p300 as an epigenetic master regulator of transcriptional escape pathways. Its lead asset, TT125-802, is an oral, selective CBP/p300 bromodomain inhibitor currently in Phase 1 trials, demonstrating initial monotherapy activity and planned for combination regimens to prevent resistance. Tolremo's strategy aims to transform targeted therapies into durable treatments across solid and hematological tumors.

Oncology

Technology Platform

Proprietary phenotypic screening platform to identify master regulators of transcriptional non-oncogene addiction and resistance pathways, leading to the discovery of CBP/p300 as a key target.

Funding History

2
Total raised:$33.5M
Series A$28M
Seed$5.5M

Opportunities

The universal challenge of non-genetic resistance to targeted therapies presents a massive, untapped market.
TT125-802's potential to be combined with a wide array of existing and future targeted drugs creates a platform-like opportunity with broad applicability across oncology.
Early monotherapy activity signals could accelerate development and attract high-value partnership interest.

Risk Factors

The primary risk is clinical validation; the novel mechanism must prove safe and effective in human trials, especially in combination.
Safety concerns related to inhibiting the broadly acting CBP/p300 proteins could limit dosing.
The company also faces significant financing and execution risks inherent to capital-intensive oncology drug development.

Competitive Landscape

Competition exists from other companies targeting epigenetic regulators (e.g., BET inhibitors) and adaptive resistance pathways. However, Tolremo's specific focus on CBP/p300 bromodomain inhibition for transcriptional addiction is a differentiated approach. They also compete for funding and partnership attention in the crowded oncology innovation space.

More companies in Small Molecule Drugs →More companies in Switzerland →